ClinicalTrials.gg
CompletedNCT02136953Updated Oct 4, 2019

Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change

An interventional study of Exercise and Cognitive Behavioural Therapy (CBT) in Obsessive-Compulsive Disorder and Cognition Disorders, sponsored by Sunnybrook Health Sciences Centre. Completed at 3 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Obsessive compulsive disorder (OCD) is a severe and debilitating anxiety disorder afflicting 2% of the population. Cognitive behavioural therapy (CBT) is considered first line psychological treatment for OCD, but there are a large number of treatment non-responders, and the majority of responders have residual symptoms. Aerobic exercise has shown potential benefit for general mood and anxiety disorders, but has not been widely tested in OCD. This study will examine the additive benefits of a standard 12-week aerobic exercise program to a standard 12-week CBT protocol in the treatment of OCD. The study will test if Exercise+CBT results in significantly better clinical outcomes compared to either treatment alone or no treatment at all. Treatment outcomes will be assessed in relation to symptom and cognitive measures of clinical improvement.

Read the detailed description

This study aims to determine if a standard, evidence-based 12-week aerobic exercise program results in significant reduction of obsessive-compulsive symptom severity and associated cognitive dysfunction as a stand-alone intervention and when combined with the first-line psychological treatment, cognitive behavioural therapy (CBT). There are 3 broad aims to this study: 1) to compare the relative efficacy of Exercise, CBT, and their combination (CBT+Ex) versus a non-treatment waitlist control (WL), 2) to examine the extent to which neuropsychological features of OCD improve following treatments, and 3) to determine the extent to which the BDNF gene and protein are a) associated with learning and cognitive factors, and b) moderate symptom and cognitive change across treatments.

The study design allows for a novel, well-powered and potentially landmark study on the impact of exercise on obsessive-compulsive symptom severity and cognitive functioning in OCD, both as a stand-alone treatment and when augmenting CBT. If this study can demonstrate that a short aerobic exercise program of 12 weeks duration can confer significant clinical gains for those suffering with OCD, then it could easily be translated into highly accessible, routine clinical care. Further, demonstration of improvement in OCD-associated cognitive dysfunction, given the refractory nature of the illness, would provide another avenue into the long-term enhancement of outcomes for this chronically affected population.

02

Conditions studied

  • Obsessive-Compulsive Disorder
  • Cognition Disorders

Keywords

  • Obsessive-Compulsive Disorder
  • Exercise
  • Cognitive Behavior Therapy
  • Cognitive Behavioral Therapy
  • Treatment Efficacy
  • Brain-Derived Neurotrophic Factor
03

In context

Obsessive-Compulsive Disorder

626 studies on the registry are indexed under Obsessive-Compulsive Disorder; 162 are open to participants now.

This study's enrollment of 125 is above the median of 45 across 510 interventional studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Sunnybrook Health Sciences Centre is the lead sponsor of 582 studies on the registry; 133 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presenting with DSM-5 diagnosed OCD
  • Score of >16 on the Yale-Brown Obsessive Compulsive Scale (YBOCS)
  • A Physical Activity Readiness Questionnaire (PAR-Q) score of ≤1
  • If on medications for OCD, must be stabilized, i.e. are currently receiving an adequate dose (equivalent of 40mg/day of fluoxetine) for an adequate duration (at least 12 weeks of treatment) prior to the initiation of the study
  • Has physician letter of approval for safe participation in fitness assessment and exercise protocol

Exclusion criteria

Exclusion Criteria:

  • Previous course of CBT treatment (≥ 8 sessions) in past two years
  • Engaging in an active exercise regimen (>2 days/wk of moderate-to-vigorous exercise training) at the time of recruitment
  • Concurrent diagnosis of a severe mood disorder, schizophrenia or other psychotic disorders, or substance abuse/dependence
  • Suspected organic pathology
  • Active comorbid medical condition that may require urgent intervention during the treatment
  • Incapable of providing informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Exercise

    12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.

    Behavioral: Exercise

  • Active comparator
    Cognitive Behavioural Therapy (CBT)

    12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.

    Behavioral: Cognitive Behavioural Therapy (CBT)

  • Experimental
    Exercise and CBT

    Combined 12-week Exercise program and CBT.

    Behavioral: Exercise · Behavioral: Cognitive Behavioural Therapy (CBT)

  • No intervention
    Waitlist Condition

    12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.

Interventions

  • BehavioralExercise

    12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.

  • BehavioralCognitive Behavioural Therapy (CBT)

    CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.

06

What researchers measure

Primary outcomes

  1. Change from baseline in OCD symptom severity, as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

    OCD symptom severity will be measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS).The YBOCS is a standardized rating scale measuring 10 items pertaining to obsessions and compulsions on a 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms). Both the self-report and clinician interview versions of the YBOCS have been shown to possess high internal consistency and validity.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change from baseline in cognitive domains sensitive to OCD, as measured by a targeted neuropsychological battery

    We have included core paper-and-pencil and computerized tests, such as those from the Cambridge Neuropsychological Test Automated Battery (CANTAB), which tap separable cognitive domains that are sensitive to OCD. CANTAB measures are standardized and have been shown to discriminate amongst many neurological and psychiatric illnesses To avoid practice effects, measures were selected to have either alternate form or to be amenable to calculation of reliable change indices (RCIs). RCIs will be used to determine if neuropsychology performance scores change significantly over time.

    Time frame: Baseline to 12 weeks

Other outcomes

  1. Change from baseline in fitness level as measured by incremental maximal exercise test

    Participants will undergo an incremental maximal exercise test on an electronically braked cycle ergometer (Lode Corival) to establish level of fitness. Peak heart-rate, peak watts, total duration and ratings of perceived exertion are all recorded during the test. Peak heart-rate will also be used to tailor the aerobic Exercise treatment to the individual participant in order to maximize health benefit.

    Time frame: Baseline to 12 weeks

07

Study locations

3 sites
  • St. Joseph's Healthcare Hamilton at McMaster University
    Hamilton, Ontario L8N 4A6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Centre for Addiction and Mental Health
    Toronto, Ontario M5T 1R8, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02136953
Collaborators
Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health, McMaster University, Toronto Metropolitan University
Responsible party
Dr. Neil Rector (Research Scientist, Psychologist, and Director of the Mood and Anxiety Treatment and Research Program, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
May 13, 2014
Start date
May 2014
Primary completion
Oct 2017
Completion
Aug 30, 2019
Last update
Oct 4, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion